A Gene Therapy Study for Hemophilia B

Hemophilia B Clinical Trial

Official title:

Gene Therapy, Open-label, Dose-escalation Study of PF-06838435 (SPK-9001) [Adeno-associated Viral Vector With Human Factor IX Gene] in Subjects With Hemophilia B

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02484092
• Other study ID #: C0371005
• Secondary ID: SPK-9001-101
• Status: Completed
• Phase: Phase 2
• Start date: November 18, 2015
• Est. completion date: April 8, 2019

Study information

• Verified date: June 2020
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Phase 1/2, Open-Label, Non-Randomized, Dose-Escalation Study of SPK-9001 in Subjects with Hemophilia B.

Description:

Hemophilia B, or Christmas disease, is a genetic bleeding disorder resulting in the lack of ability to produce blood-clotting factor IX (FIX). Individuals with hemophilia B suffer repeated bleeding events, which can cause chronic joint disease and sometimes leads to death due to the inability for blood to clot efficiently. This chronic joint disease can have significant physical, psychosocial, and quality-of-life effects, including financial burden. The current treatment is intravenous infusion of FIX protein products, either prophylactically or in response to bleeding.

The approach being tested in this study uses a novel recombinant adeno-associated virus (AAV), which in nature causes no disease, to deliver the human factor IX (hFIX) gene to the liver cells where FIX is normally made. Recent data of a gene therapy study showed preliminary encouraging results with the approach of using an AAV vector carrying the factor IX gene. This study will seek to determine the safety and kinetics of a single IV infusion of SPK-9001 (a novel AAV vector carrying a high specific activity factor IX variant).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: April 8, 2019
• Est. primary completion date: April 8, 2019
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Able to provide informed consent and comply with requirements of the study

• Males =18 y.o. with confirmed diagnosis of hemophilia B (=2 IU/dL or =2% endogenous factor IX)

• Received =50 exposure days to factor IX products

• A minimum average of 4 bleeding events per year requiring episodic treatment of factor IX infusions or prophylactic factor IX infusions

• No measurable factor IX inhibitor as assessed by the central laboratory and have no prior history of inhibitors to factor IX protein

• Agree to use reliable barrier contraception until 3 consecutive samples are negative for vector sequences

Exclusion Criteria:

• Evidence of active hepatitis B or C

• Currently on antiviral therapy for hepatitis B or C

• Have significant underlying liver disease

• Have serological evidence* of HIV-1 or HIV-2 with CD4 counts =200/mm3 (* subjects who are HIV+ and stable with CD4 count >200/mm3 and undetectable viral load are eligible to enroll)

• Neutralizing antibodies reactive with AAV-Spark100 above and/or below a defined titre

• Participated in a gene transfer trial within the last 52 weeks or in a clinical trial with an investigational drug within the last 12 weeks

• Unable or unwilling to comply with study assessments

Related Conditions & MeSH terms

• Hemophilia A
• Hemophilia B

Intervention

Biological:
• SPK-9001
A novel, bioengineered adeno-associated viral vector carrying human factor IX variant

Locations

Country	Name	City	State
Australia	Royal Prince Alfred Hospital	Camperdown/Sydney	New South Wales
United States	University of Mississippi Medical Center	Jackson	Mississippi
United States	Mississippi Center for Advanced Medicine	Madison	Mississippi
United States	Weill Cornell Medicine - New York Presbyterian Hospital	New York	New York
United States	The Children's Hospital of Philadelphia	Philadelphia	Pennsylvania
United States	UC Davis Comprehensive Cancer Center	Sacramento	California
United States	UC Davis CTSC Clinical Research Center	Sacramento	California
United States	UC Davis Ellison Ambulatory Care Clinic	Sacramento	California
United States	UC Davis Investigational Pharmacy	Sacramento	California
United States	UC Davis Medical Center	Sacramento	California

Sponsors (1)

Lead Sponsor	Collaborator
Pfizer

Countries where clinical trial is conducted

United States,  Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Clinically Significant Change From Baseline in Physical Examination Findings	Physical examination included examination of the head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. The examination assessed the participants for any potential changes in general appearance, the respiratory and cardiovascular systems, as well as towards participant reported symptoms. Findings were considered to be clinically significant based on investigator's decision.	Baseline up to Week 52
Primary	Number of Participants With Clinically Significant Change From Baseline in Vital Signs	Vital signs (temperature, respiratory rate, pulse rate, height, weight, systolic and diastolic blood pressure) were obtained with participant in the seated position, after having sat calmly for at least 5 minutes. Clinical significance of vital signs was determined at the investigator's discretion.	Baseline up to Week 52
Primary	Number of Participants With Clinical Laboratory Abnormalities Reported as TEAE	Following parameters were analyzed for laboratory examination: hematology (neutrophils, lymphocytes, monocytes, eosinophils, basophils, red blood cell [RBC] count, hemoglobin, hematocrit, platelet count); liver function (albumin, total bilirubin, total protein, direct bilirubin, indirect bilirubin, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, alkaline phosphatase, GGT); Lipid panel (HDL, VLDL, triglycerides, total cholesterol); clinical chemistry (sodium, potassium, chloride, bicarbonate, glucose, phosphate, serum creatinine, BUN); urinalysis (specific gravity, pH, glucose, protein, blood, ketones; coagulation, immunology, etc. Investigators determined which laboratory abnormalities were reported as treatment-emergent adverse events (TEAEs).	Baseline up to Week 52
Primary	Number of Participants With Drug -Related TEAEs and Serious Adverse Events (SAEs)	An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. A serious adverse event (SAE) was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect. AEs included both SAEs and AEs. An AE was regarded as TEAE if the start date was on or after the infusion of SPK-9001 but before participant's last visit on study (or the date of withdrawal/the date of being lost to follow-up). Severe TEAEs were TEAEs that interfered significantly with participants' usual function. Treatment-related TEAEs were determined by the investigator.	Baseline up to Week 52
Primary	Number of Participants With Positive Immune Reponses Against Adeno-associated Virus Vector (AAV) Capsid	Peripheral blood mononuclear cells (PBMC) results by interferon gamma enzyme-linked immunospot assay (ELISPOT) to assess cellular immune responses to AAV capsid and to FIX were presented. The ELISPOT is a type of assay that focuses on quantitatively measuring the frequency of cytokine secretion for a single cell. The positive ELISPOT results suggested a T-cell reaction to capsid protein.	Baseline up to Week 52
Primary	Number of Participants Who Reached > 150% Vector-derived FIX:C Activity Level After SPK-9001 Infusion	Based on non-clinical studies in non-human primates (NHPs), it was not predicted that vector-derived FIX:C activity levels >150% of normal would be achieved in this study. However, thrombin antithrombin (TAT) levels as thrombotic potential were to be measured if vector derived FIX:C activity levels >150% of normal were achieved in any participant during the study. Blood samples for TAT at Day 0 visit (prior to FIX protein product infusion) were used to establish baseline value.	Baseline up to Week 52
Primary	Number of Participants With FIX Inhibitor	FIX inhibitors were measured using the Bethesda assay from the central and local laboratory. The Bethesda assay measures the amount of factor (FIX) inactivated when the plasma from the patient is incubated with an external source of factor for 2 hours at 37ºC. Inhibitor levels are quantified in Bethesda units (BU). An inhibitor titer of = 0.6 BU/ml is to be taken as clinically significant.	Baseline up to Week 52
Primary	Incremental Recovery of FIX Product	Incremental recovery was determined as the peak factor level recorded within the first 3 hours after infusion and was reported as (IU/ml)/(IU/kg), using the formula:([Activity IU/mL peak post infusion] - [Activity IU/mL pre-infusion]) / (IU/kg infused).	Day 0 and Week 52
Secondary	FIX:C Activity	All samples collected from participants for plasma FIX activity levels were analyzed and used to determine peak and steady-state vector-derived circulating FIX activity levels. The vector-derived endogenous (not affected by intercurrent FIX product infusions) FIX:C activity levels were characterized by post-treatment population mean. Dose escalation and dose level expansion strategies were employed in the study based on vector-derived FIX activity levels as well as any immune responses against AAV capsid. Steady-state levels were based on 2 separate vector-derived FIX:C activity level measurements (at least 2 weeks apart) starting from Week 8-12 with adequate washout.	Baseline up to Week 52
Secondary	Change From Baseline in FIX:C Antigen Level at Steady State	The vector-derived endogenous (not affected by intercurrent FIX product infusions) FIX:C activity antigen levels were characterized by post-treatment population mean.	Week 12 up to Week 52